Newly diagnosed immune thrombocytopenia (ITP) is a relatively common disorder of
childhood that does not require an exhaustive laboratory workup for diagnosis. A history and …

Immune thrombocytopenia (ITP) in children is a relatively mild and self‐limited disorder with
the majority of children demonstrating normalization of platelet count by 12 months from …

Background: The thrombopoietin receptor agonist eltrombopag has been shown to be safe
and effective for children with chronic immune thrombocytopenia (ITP). The aim of the …

Immune thrombocytopenia (ITP), an acquired autoimmune disorder of low platelets and risk
of bleeding, has a substantial impact on health‐related quality of life (HRQoL). Patients with …

Due to the low prevalence of afibrinogenemia, epidemiologic data on afibrinogenemia are
limited, and no data are available on health-related quality of life (HRQoL). We conducted a …

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with isolated
thrombocytopenia and risk of hemorrhage. Treatment with eltrombopag increases and …

Immune thrombocytopenia (ITP) is a disease of heterogenous origin characterized by low
platelet counts and an increased bleeding tendency. Three disease phases have been …

免疫性血小板减少症(ITP) 是儿童时期最为常见的出血性疾病, 由多种自身免疫机制介导,
以孤立性血小板减少为主要临床特点. 儿童ITP 通常急性起病, 相当比例的患儿可追溯到前驱 …

The thrombopoietin receptor agonists (TPO-RAs) are a class of platelet growth factors used
to treat immune thrombocytopenia (ITP) in children and adults. Romiplostim is a peptide …

El manejo de la trombocitopenia inmune es motivo de discusión en lo concerniente a
evolución, diagnóstico, pronóstico y tratamiento. Se han publicado varias guías que …